Trexquant Investment LP Raises Stake in Xencor, Inc. $XNCR

Trexquant Investment LP boosted its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 60.2% in the first quarter, HoldingsChannel reports. The fund owned 133,360 shares of the biopharmaceutical company’s stock after acquiring an additional 50,119 shares during the period. Trexquant Investment LP’s holdings in Xencor were worth $1,419,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new position in Xencor during the 4th quarter valued at about $34,000. CWM LLC lifted its position in Xencor by 195.5% during the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 2,231 shares during the period. AlphaQuest LLC purchased a new position in Xencor during the 1st quarter valued at about $56,000. Mackenzie Financial Corp purchased a new position in Xencor during the 4th quarter valued at about $101,000. Finally, GAMMA Investing LLC lifted its position in Xencor by 348.5% during the 1st quarter. GAMMA Investing LLC now owns 9,629 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 7,482 shares during the period.

Xencor Stock Performance

NASDAQ:XNCR opened at $8.55 on Friday. The firm has a market cap of $609.79 million, a P/E ratio of -3.56 and a beta of 0.82. Xencor, Inc. has a fifty-two week low of $6.92 and a fifty-two week high of $27.24. The firm has a 50-day simple moving average of $8.29 and a two-hundred day simple moving average of $9.64.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.37. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. The firm had revenue of $43.61 million during the quarter, compared to analyst estimates of $22.59 million. During the same period in the previous year, the business posted ($1.07) earnings per share. The business’s revenue for the quarter was up 82.4% on a year-over-year basis. On average, equities research analysts predict that Xencor, Inc. will post -3.68 EPS for the current year.

Insiders Place Their Bets

In other Xencor news, Director Richard J. Ranieri sold 2,993 shares of Xencor stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the sale, the director owned 19,183 shares of the company’s stock, valued at approximately $176,867.26. The trade was a 13.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ellen Feigal sold 2,993 shares of Xencor stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $9.22, for a total transaction of $27,595.46. Following the completion of the sale, the director directly owned 19,183 shares of the company’s stock, valued at approximately $176,867.26. This trade represents a 13.50% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,194 shares of company stock valued at $103,209. Company insiders own 4.76% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on XNCR shares. Wedbush reissued an “outperform” rating and set a $26.00 price target on shares of Xencor in a research report on Tuesday. Royal Bank Of Canada lowered their price target on shares of Xencor from $32.00 to $15.00 and set an “outperform” rating for the company in a research report on Thursday, August 21st. Wells Fargo & Company reduced their price objective on shares of Xencor from $33.00 to $27.00 and set an “overweight” rating for the company in a research note on Thursday, August 7th. Finally, Bank of America lowered shares of Xencor from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $23.00 to $12.00 in a research note on Wednesday. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.25.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.